To examine the decline in risk of endometrial cancer after discontinuation of use of conjugated estrogens, we conducted a case-control study in a prepaid health plan. We identified 318 patients who had endometrial cancer but had no history of bilateral oophorectomy and had been in the Southern California (United States) Kaiser Foundation Health Plan for more than 10 years. For each patient, one or two control members were selected, 599 in all, matched for age and duration of membership at the time of cancer detection and who had had neither hysterectomy nor bilateral oophorectomy. A history of prescriptions for conjugated estrogens and of potential confounders was obtained for each subject by reviewing outpatient medical records. Rate ratios (RR) contrasting users with nonusers were estimated by time of latest prescription. We found that estrogen-induced risk of endometrial cancer decreases rapidly as the estrogen-free interval increases. The RR estimates, adjusted for duration of use and potential confounding factors, declined from 5.0 for those receiving their latest prescription within 24 months (95 percent confidence limits [CL]=2.6–9.8), to 1.8 for those receiving their latest prescription within 24 to 48 months (CL=0.9–3.7), to values near one for each latest prescription interval earlier than 48 months ago (P for trend = 0.0004). For those who used conjugated estrogens extensively (five or more prescriptions, five to 10 years ago), the RR estimate declined from 5.1 for those whose latest prescription was within two years to 0.6 yr for those whose latest prescription was four to five years previously (P for trend = 0.05).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Voigt LF, Weiss NS. Epidemiology of endometrial cancer. In: Surwit EA, Alberts DS, eds. Endometrial Cancer. Boston, MA (USA): Kluwer Academic Publishers, 1989: 1–21.
Herrinton LJ, Weiss NS. Postmenopausal unopposed estrogens: characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 1993; 3: 308–18.
Jick H, Watkins RN, Hunter JR et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979; 300: 218–22.
Hulka BS, Grimson RC, Greenberg BG et al. “Alternative” controls in a case-control study of endometrial cancer and exogenous estrogen. Am J Epidemiol 1980; 112: 376–87.
Stavraky KM, Collins JA, Donner A, Wells GA. A comparison of estrogen use by women with endometrial cancer, gynecologic disorders, and other illnesses. Am J Obstet Gynecol 1981; 141: 547–55.
Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989; 59: 445–7.
Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990; 162: 148–54.
Weiss NS, Szekely DR, English DR, Schweid AI. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979; 242: 261–4.
Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986; 124: 434–41.
Mack TM, Pike MC, Henderson BE et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976; 294: 1262–7.
Shapiro S, Kelly JP, Rosenberg L et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313: 969–72.
Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins use patterns over time. Obstet Gynecol 1985; 65: 441–6.
Gruber JS, Luciani CT. Physicians changing postmenopausal sex hormone prescribing regimens. In: Mortenson LE, Engstrom PF, Anderson PW, eds. Advances in Cancer Control: Health Care Financing and Research. Proceedings of the Association of Community Cancer Centers 11th National Meeting; Oncology—surviving the 80's: a combined meeting of the Association of Community Cancer Centers/Association of American Cancer Institutes, held in Washington, DC, March 13–17, 1985. New York, NY (USA): Alan R. Liss, 1986: 325–35.
Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993; 81: 265–71.
Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–7.
Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume I: The Analysis of Case-control Studies. Lyon, France: International Agency for Research on Cancer, 1980; IARC Sci. Pub. No. 32: 5–338.
Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York, NY (USA): Wiley, 1989. (Wiley series in probability and mathematical statistics. Applied probability and statistics.).
Author information
Authors and Affiliations
Additional information
This research was supported by National Institutes of Health contract NO1 CP 95680.
Rights and permissions
About this article
Cite this article
Finkle, W.D., Greenland, S., Miettinen, O.S. et al. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). Cancer Causes Control 6, 99–102 (1995). https://doi.org/10.1007/BF00052769
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00052769